RPCI Cancer Talk

Wednesday, October 11, 2017 - 2:30pm
Cancer Support

I grew up thinking I wanted to be a reconstructive plastic surgeon, because I wanted to change lives. I felt it was my calling to make life better for those who struggled, but the amount of school was rather daunting, so I chose a different route in computer science.

Tuesday, October 10, 2017 - 2:50pm
Cancer Research & News

Because of AML’s aggressive nature, it traditionally requires aggressive—and immediate—treatment that involves intensive, high-dose chemotherapy and many weeks in the hospital. For older patients, however, such grueling treatment isn’t always promising, and many are mistakenly advised that their time and options are limited.

Friday, October 6, 2017 - 3:34pm
Patient Stories

Four weeks after her 33rd birthday, Crystal found a lump in her breast. When she told a good friend and co-worker — whose mother happened to be in treatment for metastatic breast cancer — the friend told her, “Don’t mess around.”

Friday, October 6, 2017 - 11:26am
Life & Wellness
Borderline ovarian tumors represent a small subset of epithelial ovarian tumors. Because it’s an uncommon and unfamiliar diagnosis, it’s often misunderstood.
Monday, October 2, 2017 - 4:18pm
Patient Stories

I was told the tumor was inoperable and I had two years to live if I received chemotherapy and radiation. Just two years.

Saturday, September 30, 2017 - 9:00am
Cancer Research & News

We have heard lots of information lately about talcum powder use and the risk of ovarian cancer.

Friday, September 29, 2017 - 5:05pm
Cancer Support

Hormone therapy causes side effects that can have a serious impact on the patient's quality of life, but men are often reluctant to talk about them or ask for help. A new education group aims to get the word out: "There is hope."

Thursday, September 28, 2017 - 2:57pm
Cancer Research & News

“Initially, ovarian cancer, melanoma, and some sarcomas are the three main targets,” says Dr. Koya, “but the clinical trial is open for patients with other cancers who meet the eligibility requirements."